- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02239822
Electrical Stimulation in Patients With Unipolar Major Depression (TREND2)
Double Blinded Randomized Trial of eTNS as Adjuvant Treatment for Major Unipolar Depressive Disorder.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
SP
-
São Paulo, SP, Brazil, 04005-000
- Hospital do Coracao
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatients with non-psychotic, unipolar Major Depressive Disorder assessed via the MINI structured interview and legally capacitated to sign the informed consent for participation in the study;
- A score of ≥ 14 on the HAM-D17 with Item 1 (depressed mood) ≥ 2;
- A history of treatment failure with at least 3 adequate trials antidepressants over the previous 6 weeks and less than 6 medications, with no change in antidepressant medication or dose within the previous 6 weeks, and ongoing use of at least one antidepressant (which will continue during participation in the study);
- Patients with suicidal ideation are eligible only if the thoughts of death or of life not being worth living are not accompanied by a plan or intention for self-harm and lack of self-harming attempt in the past 6 months;
- Patients with appropriate support to be compliant with the study protocol.
Exclusion Criteria:
- Patient is mentally or legally incapacitated, unable to give informed consent;
- Patients with psychosis (psychotic depression, schizophrenia, or schizoaffective diagnoses (lifetime); bipolar disorder (lifetime); dementia (lifetime); delirium or any substance abuse disorder within the past 6 months; eating disorder within the past year; obsessive-compulsive disorder (lifetime); post-traumatic stress disorder within the past year; acute risk for suicide or self-injurious behavior. Patients with diagnostic uncertainty or ambiguity (e.g. rule-out pseudo-dementia of depression) will be excluded;
- Patients currently receiving more than six medications for treatment of MDD;
- Patients with exposure to ECT or rTMS or any investigational treatment (for any disorder) within the past 6 months;
- Prior VNS and/or DBS therapy (lifetime);
- Past history of skull fracture; cranial surgery entering the calvarium; space occupying intracranial lesion; stroke, CVA, or TIAs; cerebral aneurysm; Parkinson's or Huntington's disease; or Multiple Sclerosis.
- Current pregnancy, breast feeding, plans to become pregnant during the study, or not using a medically accepted means of contraception;
- Other medical conditions that would increase the risk of infection or surgical related morbidity and/or would affect compliance with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Stimulation
Patients assigned to active stimulation arm will receive electrical stimulation during the study.
|
Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study. Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study. The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks.
Other Names:
|
Placebo Comparator: Placebo Stimulation
Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks.
After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
|
Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study. Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study. The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify a efficacy of eTNS of the V1 branch of the trigeminal nerve
Time Frame: 48 weeks
|
We will use the Hamilton Rating Scale for Depression (HRSD) 17 scores as the main outcome measure to assess the efficacy of sTNS of the V1 branch of the trigeminal nerve as adjunctive treatment for MDD.
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify the tolerability of eTNS stimulation
Time Frame: 48 weeks
|
Tolerability will be evaluated by the records of adverse effects observed during the randomized, open stimulation.
We will apply the Ugvalg for Kliniske Undersgelser (UKU) scale at all visits for all patients and to compare scores between groups.
Adverse events will be categorized using the MedDRA Medical Dictionary for Regulatory Activities.
Complications reported by active and sham stimulation groups will be compared.
The complication risk will be calculated based on the overall study duration.
|
48 weeks
|
Identify the long-term recurrence rate of eTNS therapy
Time Frame: 48 weeks
|
We will calculate the recurrence rate of all participants at the end of the open label prospective follow-up.
Recurrence is defined as return of HAM-17 scores equal to or superior to the original, after the patient has lodged during partial response (20% decrease of the initial score) or complete response (50% decrease of the initial score).
|
48 weeks
|
Identify the duration of the placebo effect
Time Frame: 48 weeks
|
To evaluate the duration of the placebo effect in participants randomized to sham stimulation during the initial 12 weeks of the trial.
The mean, median and the standard deviation of the interval time to recurrence will be calculated on placebo stimulation.
|
48 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alessandra Gorgulho, MD, MSc, Hospital do Coracao
- Principal Investigator: Antonio De Salles, M.D., Ph.D., Hospital do Coracao
- Study Director: Otavio Berwanger, MD,PhD, Hospital do Coracao
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 271/2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
Clinical Trials on Stimulation of the trigeminal nerve (active stimulation)
-
Hospital do CoracaoCompleted
-
Dr. Rafael FreireActive, not recruitingGeneralized Anxiety Disorder | Social Anxiety Disorder | Panic DisorderCanada
-
Instituto de Oftalmología Fundación Conde de ValencianaCompletedDry Eye | Neuropathic Pain | Eye PainMexico
-
Olive View-UCLA Education & Research InstituteBoston Scientific Corporation; Epilepsy FoundationCompleted
-
Dr. Rafael FreireRecruitingGeneralized Anxiety DisorderCanada
-
Santa Casa Medical SchoolUnknownMajor Depressive Disorder | Elderly
-
Santa Casa Medical SchoolFaculdade de Ciências Médicas da Santa Casa de São PauloUnknownDepressive SymptomsBrazil
-
University of California, Los AngelesUnited States Department of Defense; VA Greater Los Angeles Healthcare SystemCompleted
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
NeuroSigma, Inc.Olive View-UCLA Education & Research InstituteUnknownSeizure DisorderUnited States